International Journal of Molecular Medical Science, 2024, Vol.14, No.4, 227-238 http://medscipublisher.com/index.php/ijmms 234 in harmonizing data from different platforms and ensuring that the integrated datasets are both comprehensive and accurate (Davalos and Esteller, 2022; Feinberg and Levchenko, 2023). 8.3 Personalized medicine and epigenetics The potential of epigenetics in personalized medicine is immense, particularly in the context of colon cancer. Epigenetic biomarkers, such as DNA methylation patterns, can be used for early diagnosis, prognosis, and prediction of treatment response (Jung et al., 2020; Davalos and Esteller, 2022; Costa et al., 2023). Personalized epigenetic therapies, which target specific epigenetic modifications, are also being explored. For example, inhibitors of DNA methyltransferases and histone deacetylases have shown promise in preclinical and clinical studies (Costa et al., 2023). However, the implementation of personalized epigenetic medicine faces several hurdles. These include the need for reliable and reproducible biomarkers, the development of targeted epigenetic drugs with minimal off-target effects, and the establishment of clinical guidelines for the use of epigenetic therapies (Cao et al., 2020; Gebrekiristos et al., 2022). The paper published in Science by Feinberg and Levchenko in 2023 explores the complex relationship between epigenetics and cancer, emphasizing how regulatory networks influence cell states and their transitions. The authors discuss how modern experimental techniques, such as single-cell analysis and epigenetic assays, have advanced our understanding of these landscapes and their roles in cancer progression. They propose that using concepts from the physical sciences, such as entropy and potential energy landscapes, can provide a quantitative analysis of the variability and plasticity observed in cancer cells. Figure 1 summarizes the intricate dynamics of gene regulatory networks and epigenetic landscapes, highlighting how changes in these landscapes drive the phenotypic plasticity and heterogeneity observed in cancer cells (Feinberg and Levchenko, 2023). Figure 1 Epigenetic landscapes and phenotypic plasticity in cancer (Adopted from Feinberg and Levchenko, 2023) Imagine Caption: Regulatory networks can define the number and probabilities of stable cellular states adopted by a cell population, representing attractors in the epigenetic landscape. Diverse inputs can promote transitions (and corresponding phenotypic plasticity) between cellular states within landscapes corresponding to the normal tissue (fewer attractors) and cancerous tumors (emergence of new attractors), as defined by parameters P1 and P2 that correspond to effective concentrations of landscape-defining molecules. (Adopted from Feinberg and Levchenko, 2023) 8.4 Future research priorities Future research in the field of colon cancer epigenetics should focus on several key areas. First, there is a need for more comprehensive and longitudinal studies to understand the temporal dynamics of DNA methylation changes during cancer progression (Jung et al., 2020; Tao et al., 2020). Second, the development of more sensitive and specific technologies for detecting and quantifying DNA methylation will be crucial (Li et al., 2020; Feinberg and Levchenko, 2023). Third, integrating multi-omics data to build detailed epigenetic maps of colon cancer will provide deeper insights into the molecular mechanisms underlying the disease (Dai et al., 2020; Cao et al., 2020).
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==